Patents by Inventor Jung-Won WOO

Jung-Won WOO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210177945
    Abstract: Provided is a method for administering a recombinant human growth hormone GX-H9 for treating growth hormone deficiency. Particularly, the present disclosure relates to a pharmaceutical composition for treating growth hormone deficiency, containing a recombinant hGH GX-H9 and a pharmaceutically acceptable carrier, in which the recombinant GX-H9 is administered once a week with a dosage of 0.1 to 0.3 mg per weight kg of a patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient. Further, the present disclosure relates to a method for treating growth hormone deficiency including administering an recombinant hGH GX-H9 to a patient with growth hormone deficiency once a week with a dosage of 0.1 to 0.3 mg per weight kg of the patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient.
    Type: Application
    Filed: February 16, 2017
    Publication date: June 17, 2021
    Inventors: Tae Kyung Kim, Young_Joo Ahn, Jung Won Woo, Ji-Eun Cha, Joan Yoon Ji Lee, Woo Ick Jang
  • Publication number: 20190224281
    Abstract: A method for treating growth hormone deficiency, including administering a human growth hormone fusion protein (GX-H9). A method includes administering a pharmaceutical composition containing an hGH fusion protein (GX-H9) and a pharmaceutically acceptable carrier, wherein the fusion protein (GX-H9) is administered once a week at a dose of 0.4 to 1.6 mg per body weight kg of a pediatric patient, or administered once every two weeks at a dose of 0.8 to 3.2 mg per body weight kg of a pediatric patient.
    Type: Application
    Filed: August 30, 2017
    Publication date: July 25, 2019
    Applicants: GENEXINE, INC., HANDOK INC.
    Inventors: Tae Kyung KIM, Jung Won WOO, Joan Yoon Ji LEE, Young-Joo AHN, Ji-Eun CHA, Hyou Young RHIM, Woo Ick JANG
  • Publication number: 20180264082
    Abstract: The present invention relates to a method for treating anemia using a long-acting EPO formulation, and more specifically, a method for treating patients with anemia by confirmation of safe, long-acting, and optimal effective dosage and usage in administering a fusion polypeptide which comprises an EPO and an immunoglobulin hybrid Fc to patients with anemia. The method of administering the fusion polypeptide employs an appropriate dosage and usage which not only shows an excellent long-acting property compared to the existing EPO products but also minimizes cardiovascular side effects that may occur due to a rapid increase in hemoglobin level, which is an effect of anemia treatment.
    Type: Application
    Filed: January 8, 2016
    Publication date: September 20, 2018
    Applicants: GENEXINE, INC., GREEN CROSS CORPORATION
    Inventors: Sang-In YANG, Jung-Won WOO, Se Hwan YANG, Young Chul SUNG, Doo Hong PARK, Min Woo KIM